How to buy Annexon stock | $18.49

Annexon Inc is a biotechnology business based in the US. Annexon shares (ANNX) are listed on the NASDAQ and all prices are listed in US Dollars. Annexon employs 57 staff and has a market cap (total outstanding shares value) of 0.00.

Annexon stock price (NASDAQ: ANNX)

Use our graph to track the performance of ANNX stocks over time.

Annexon shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$18.49
52-week range	$15.52 - $35.99
50-day moving average	$19.67
200-day moving average	$21.21
Wall St. target price	$38.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.86

Buy Annexon shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Annexon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Annexon price performance over time

Historical closes compared with the close of $18.49 from 2021-10-22

1 week (2021-10-15)	-15.95%
1 month (2021-09-23)	-15.30%
3 months (2021-07-23)	-11.95%
6 months (2021-04-23)	-12.29%

1 year (2020-10-23)	-24.35%
2 years (2019-10-19)	N/A
3 years (2018-10-19)	N/A
5 years (2016-10-19)	N/A

Annexon financials

Gross profit TTM	$0
Return on assets TTM	-26.02%
Return on equity TTM	-46.63%
Profit margin	0%
Book value	$7.71
Market capitalisation	$843.3 million

TTM: trailing 12 months

Shorting Annexon shares

There are currently 1.3 million Annexon shares held short by investors – that's known as Annexon's "short interest". This figure is 8.1% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Annexon shares can be evaluated.

Annexon's "short interest ratio" (SIR)

Annexon's "short interest ratio" (SIR) is the quantity of Annexon shares currently shorted divided by the average quantity of Annexon shares traded daily (recently around 248424.08477842). Annexon's SIR currently stands at 5.19. In other words for every 100,000 Annexon shares traded daily on the market, roughly 5190 shares are currently held short.

However Annexon's short interest can also be evaluated against the total number of Annexon shares, or, against the total number of tradable Annexon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Annexon's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Annexon shares in existence, roughly 30 shares are currently held short) or 0.0578% of the tradable shares (for every 100,000 tradable Annexon shares, roughly 58 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Annexon.

Find out more about how you can short Annexon stock.

Annexon share dividends

We're not expecting Annexon to pay a dividend over the next 12 months.

Annexon overview

Annexon, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

Frequently asked questions

What percentage of Annexon is owned by insiders or institutions?
Currently 5.603% of Annexon shares are held by insiders and 100.282% by institutions. How many people work for Annexon?
Latest data suggests 57 work at Annexon. When does the fiscal year end for Annexon?
Annexon's fiscal year ends in December. Where is Annexon based?
Annexon's address is: 180 Kimball Way, South San Francisco, CA, United States, 94080 What is Annexon's ISIN number?
Annexon's international securities identification number is: US03589W1027